title: Gene profiling and circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer.
abstract: The gene profile of primary tumors, as well as the identification of circulating tumor cells (CTCs), can provide important prognostic and predictive information. In this study, our objective was to perform tumor gene profiling (TGP) in combination with CTC characterization in women with nonmetastatic breast cancer. Biological samples (from peripheral blood and tumors) from 167 patients diagnosed with stage I, II, and III mammary carcinoma, who were also referred for adjuvant/neoadjuvant chemotherapy, were assessed for the following parameters: (a) the presence of CTCs identified by the expression of CK-19 and c-erbB-2 in the peripheral blood mononuclear cell (PBMC) fraction by quantitative reverse transcription PCR (RT-PCR) and (b) the TGP, which was determined by analyzing the expression of 21 genes in paraffin-embedded tissue samples by quantitative multiplex RT-PCR with the Plexor® system. We observed a statistically significant correlation between the progression-free interval (PFI) and the clinical stage (p = 0.000701), the TGP score (p = 0.006538), and the presence of hormone receptors in the tumor (p = 0.0432). We observed no correlation between the PFI and the presence or absence of CK-19 or HER2 expression in the PBMC fraction prior to the start of treatment or in the two following readouts. Multivariate analysis revealed that only the TGP score significantly correlated with the PFI (p = 0.029247). The TGP is an important prognostic variable for patients with locoregional breast cancer. The presence of CTCs adds no prognostic value to the information already provided by the TGP.
authors.affiliation: Oncology and Hematology Department, ABC Medical School, Av. Príncipe de Gales, 821, CEP 09060-650, Santo André, SP, Brazil. rkelly@uol.com.br.
authors.forename: Renata K
authors.initials: RK
authors.lastname: Kuniyoshi
authors.affiliation: Oncology and Hematology Department, ABC Medical School, Av. Príncipe de Gales, 821, CEP 09060-650, Santo André, SP, Brazil. flaviagehrke@hotmail.com.
authors.forename: Flávia de Sousa
authors.initials: Fde S
authors.lastname: Gehrke
authors.affiliation: Oncology and Hematology Department, ABC Medical School, Av. Príncipe de Gales, 821, CEP 09060-650, Santo André, SP, Brazil. bcaalves@uol.com.br.
authors.forename: Beatriz C A
authors.initials: BC
authors.lastname: Alves
authors.affiliation: Oncology and Hematology Department, ABC Medical School, Av. Príncipe de Gales, 821, CEP 09060-650, Santo André, SP, Brazil. viviane_boas@yahoo.com.br.
authors.forename: Viviane
authors.initials: V
authors.lastname: Vilas-Bôas
authors.affiliation: Oncology and Hematology Department, ABC Medical School, Av. Príncipe de Gales, 821, CEP 09060-650, Santo André, SP, Brazil. anaestela@gmail.com.
authors.forename: Anna E
authors.initials: AE
authors.lastname: Coló
authors.affiliation: Fundação Pio XII-Hospital de Câncer de Barretos, R. Antenor Duarte Vilela, 1331, Barretos, SP, Brazil. nsousa@gmail.com.
authors.forename: Naiara
authors.initials: N
authors.lastname: Sousa
authors.affiliation: Fundação Pio XII-Hospital de Câncer de Barretos, R. Antenor Duarte Vilela, 1331, Barretos, SP, Brazil. jjnunes@gmail.com.
authors.forename: João
authors.initials: J
authors.lastname: Nunes
authors.affiliation: Oncology and Hematology Department, ABC Medical School, Av. Príncipe de Gales, 821, CEP 09060-650, Santo André, SP, Brazil. profferfonseca@gmail.com.|Biological Sciences Department, Federal University of São Paulo, R. Prof. Arthur Riedel, 275, CEP 09972-270, Diadema, SP, Brazil. profferfonseca@gmail.com.
authors.forename: Fernando L A
authors.initials: FL
authors.lastname: Fonseca
authors.affiliation: Oncology and Hematology Department, ABC Medical School, Av. Príncipe de Gales, 821, CEP 09060-650, Santo André, SP, Brazil. aurodelgiglio@gmail.com.|, Rua Mariana Correia 369, 01444-000, São Paulo, Capital, Brazil. aurodelgiglio@gmail.com.
authors.forename: Auro
authors.initials: A
authors.lastname: Del Giglio
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000145:classification / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D020869:Gene Expression Profiling; D006801:Humans; D053539:Keratin-19 / Q000235:genetics*; D007963:Leukocytes, Mononuclear / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D053539:Keratin-19; D012333:RNA, Messenger; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
keywords: Biological markers; Breast neoplasms; Cancer chemotherapy drugs; Keratin-19; Multiplex polymerase chain reaction; Transcriptome